318 related articles for article (PubMed ID: 34849999)
1. Current and future options for treating complicated skin and soft tissue infections: focus on fluoroquinolones and long-acting lipoglycopeptide antibiotics.
Eckmann C; Tulkens PM
J Antimicrob Chemother; 2021 Nov; 76(Suppl 4):iv9-iv22. PubMed ID: 34849999
[TBL] [Abstract][Full Text] [Related]
2. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis.
Agarwal R; Bartsch SM; Kelly BJ; Prewitt M; Liu Y; Chen Y; Umscheid CA
Clin Microbiol Infect; 2018 Apr; 24(4):361-368. PubMed ID: 28882727
[TBL] [Abstract][Full Text] [Related]
3. Head-to-head comparison of multi-dose oritavancin and dalbavancin for complicated infections: A propensity score-matched analysis.
Steuber TD; Gipson H; Boyett B; Belk M; Thayer B; Edwards J
Int J Antimicrob Agents; 2024 Jun; 63(6):107165. PubMed ID: 38570019
[TBL] [Abstract][Full Text] [Related]
4. New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides.
Tran TT; Gomez Villegas S; Aitken SL; Butler-Wu SM; Soriano A; Werth BJ; Munita JM
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0261420. PubMed ID: 35475634
[TBL] [Abstract][Full Text] [Related]
5. Newer treatment options for skin and soft tissue infections.
Raghavan M; Linden PK
Drugs; 2004; 64(15):1621-42. PubMed ID: 15257625
[TBL] [Abstract][Full Text] [Related]
6. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
Guskey MT; Tsuji BT
Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
[TBL] [Abstract][Full Text] [Related]
7. Current approach to skin and soft tissue infections. Thinking about continuity of care.
Blanes Hernández R; Rodríguez Pérez M; Fernández Navarro J; Salavert Lletí M
Rev Esp Quimioter; 2023 Nov; 36 Suppl 1(Suppl 1):37-45. PubMed ID: 37997870
[TBL] [Abstract][Full Text] [Related]
8. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
[TBL] [Abstract][Full Text] [Related]
9. The role of dalbavancin in skin and soft tissue infections.
Bassetti M; Peghin M; Carnelutti A; Righi E
Curr Opin Infect Dis; 2018 Apr; 31(2):141-147. PubMed ID: 29298166
[TBL] [Abstract][Full Text] [Related]
10. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review.
Thomas G; Henao-Martínez AF; Franco-Paredes C; Chastain DB
Int J Antimicrob Agents; 2020 Sep; 56(3):106069. PubMed ID: 32603683
[TBL] [Abstract][Full Text] [Related]
11. Long-Acting Lipoglycopeptides for the Treatment of Bone and Joint Infections.
Cooper CC; Stein GE; Mitra S; Abubaker A; Havlichek DH
Surg Infect (Larchmt); 2021 Oct; 22(8):771-779. PubMed ID: 33835882
[No Abstract] [Full Text] [Related]
12. Current role of oxazolidinones and lipoglycopeptides in skin and soft tissue infections.
Righi E; Carnelutti A; Bassetti M
Curr Opin Infect Dis; 2019 Apr; 32(2):123-129. PubMed ID: 30664028
[TBL] [Abstract][Full Text] [Related]
13. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
[TBL] [Abstract][Full Text] [Related]
14. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections.
Russo A; Concia E; Cristini F; De Rosa FG; Esposito S; Menichetti F; Petrosillo N; Tumbarello M; Venditti M; Viale P; Viscoli C; Bassetti M
Clin Microbiol Infect; 2016 Apr; 22 Suppl 2():S27-36. PubMed ID: 27125562
[TBL] [Abstract][Full Text] [Related]
15. Dalbavancin for the Treatment of Complicated Gram-Positive Skin and Soft Tissue Infections.
Petrakis V; Panagopoulos P; Papanas N
Int J Low Extrem Wounds; 2020 Sep; 19(3):236-241. PubMed ID: 32500744
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of oritavancin for management of skin and soft tissue infections in the emergency department: A case series.
Dretske D; Schulz L; Werner E; Sharp B; Pulia M
Am J Emerg Med; 2021 May; 43():77-80. PubMed ID: 33545550
[TBL] [Abstract][Full Text] [Related]
17. Oritavancin versus oral antibiotics for treatment of skin and skin structure infections in the emergency department.
Sacdal JPA; Cheon E; Stilwell AM; Acquisto NM; Treu CN
Am J Emerg Med; 2022 Oct; 60():223-224. PubMed ID: 35835659
[No Abstract] [Full Text] [Related]
18. Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.
Corey GR; McKinnell JA; Rybak MJ
Clin Infect Dis; 2019 Apr; 68(Suppl 3):S191-S192. PubMed ID: 30957163
[No Abstract] [Full Text] [Related]
19. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance.
Lee SY; Kuti JL; Nicolau DP
Surg Infect (Larchmt); 2005; 6(3):283-95. PubMed ID: 16201938
[TBL] [Abstract][Full Text] [Related]
20. New antibiotics in the management of acute bacterial skin and skin structure infections.
Gleghorn K; Grimshaw E; Kelly EK
Skin Therapy Lett; 2015; 20(5):7-9. PubMed ID: 26382907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
